Lyell Immunopharma, Inc. (LYEL)

Lyell Immunopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	0.13	84.68	10.65	7.76	0.66
Revenue Growth (YoY)	-99.85%	695.15%	37.31%	1080.52%	-
Gross Profit	0.13	84.68	10.65	7.76	0.66
Selling, General & Admin	66.98	117.31	89.06	46.88	39.15
Research & Development	182.95	159.19	138.69	182.24	63.6
Other Operating Expenses	-2.79	-4.75	-2.32	-9.43	0
Operating Expenses	247.14	271.74	225.43	219.69	102.75
Operating Income	-247.01	-187.06	-214.78	-211.94	-102.09
Other Expense / Income	-12.38	-3.94	35.44	-7.47	27.29
Pretax Income	-234.63	-183.12	-250.22	-204.47	-129.38
Net Income	-234.63	-183.12	-250.22	-204.47	-129.38
Preferred Dividends	0	0	0	3.58	1.14
Net Income Common	-234.63	-183.12	-250.22	-208.05	-130.52
Shares Outstanding (Basic)	251	247	136	13	5
Shares Outstanding (Diluted)	251	247	136	13	5
Shares Change	1.58%	81.79%	925.18%	144.21%	-
EPS (Basic)	-0.93	-0.74	-1.84	-15.69	-24.04
EPS (Diluted)	-0.93	-0.74	-1.84	-15.69	-24.04
Free Cash Flow	-166.38	-193.83	-191.75	-212.36	23.43
Free Cash Flow Per Share	-0.66	-0.78	-1.41	-16.02	4.32
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-190006.15%	-220.89%	-2016.68%	-2732.56%	-15538.66%
Profit Margin	-180486.15%	-216.24%	-2349.47%	-2682.49%	-19866.21%
Free Cash Flow Margin	-127984.62%	-228.89%	-1800.50%	-2737.94%	3565.75%
EBITDA	-214.38	-165.1	-236.6	-200.18	-128.12
EBITDA Margin	-164909.23%	-194.96%	-2221.55%	-2580.94%	-19500.91%
Depreciation & Amortization	20.25	18.02	13.62	4.29	1.26
EBIT	-234.63	-183.12	-250.22	-204.47	-129.38
EBIT Margin	-180486.15%	-216.24%	-2349.47%	-2636.31%	-19692.09%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).